Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company. Community Guidelines: https://www.us.sumitomo-pharma.com/social-media/index.html

Established in 1932 and headquartered in Newton, Massachusetts, Barclay Water Management, Inc. is the leading middle market water treatment supplier. We provide value to our customers by reducing their water and energy consumption while protecting the watersides of critical heat exchange equipment. Our proprietary formulations are manufactured in Company-owned ISO-9001 certified facilities and our employees are committed to total customer satisfaction. The Environmental Group, a division of Barclay Water Management, provides a range of water hygiene products and services including Legionella testing, Building Water Management Plans, cooling tower and ice machine cleaning services, as well as secondary disinfection of potable water systems utilizing monochloramine, and other technologies. Barclay Water Management, Inc. is the oldest and largest employee-owned water treatment firm in North America and was named one of America’s Top Workplaces by The Wall Street Journal. Our employees are the best educated and most experienced water treatment professionals in the industry and for more than three quarters of a century we’ve remained financially sound and customer driven. Our employee-owners enjoy a generous profit-driven compensation plan and benefit package which includes the opportunity to acquire a substantial equity ownership in our business through our Employee Stock Ownership Plan (ESOP).

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

FRAUD ALERT: Please take note that it has come to our attention that individuals purporting to work for Repligen are reaching out to prospective job applicants using fraudulent email addresses. All legitimate communications from Repligen will be sent from an individual with an email address ending in @repligen.com. If you have any concerns that a communication may be fraudulent and you would like to confirm whether it is, you may email [email protected] and someone will respond. Repligen is a bioprocessing-focused life sciences company bringing over 40 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies. Repligen headquarters is in Waltham, Massachusetts and our manufacturing facilities are located around the world. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.

Technical Expertise, Innovation & Service For more than 80 years, Technic has been a global supplier of specialty chemicals, custom finishing equipment, engineered powders, and analytical control systems to the electronic component, printed circuit board, semiconductor, industrial finishing and decorative industries. Technic is also a major supplier of engineered metal powders and flakes to the solar industry. Following the expansion of our product lines through organic growth, strategic partnerships, and acquisitions, Technic has grown to be a global leader in: - Specialty Chemicals - Surface Finishing Equipment - Engineered Powder and Flake - Analytical Control Tools Our primary end use markets include: - Semiconductors (front end manufacturing, wafer level packaging, & lead frames) - Electronic Connectors - Photovoltaic Cell Manufacturing - Electronic Components - Printed Circuit Boards - Industrial Finishing - Decorative Applications

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for virology and immunology indications. Enanta’s research and development programs are currently focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU) and the company has previously advanced clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic hepatitis B virus (HBV) infection. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Simoniz USA is headquartered in Bolton, CT with operations predominately in the eastern half of the United States and distributes products both nationally and internationally. The company manufactures a diverse product line covering a broad spectrum of markets including the commercial vehicle washing, professional detailing, retail vehicle appearance, and janitorial/ institutional cleaning. Our floor finishes, disinfectants, waxes, and all-purpose cleaners are widely used in hospitals, nursing homes, food service establishments, manufacturing plants, school systems and the hospitality industry. In new car dealerships, Simoniz offers several different programs such as "GlassCoat"​, MotoTect, and PDRPlus.

Corza Medical’s mission is to aid and champion the surgical community with outstanding products and remarkable service that save time, money and effort. We are a leading provider of medical devices and Biosurgery serving surgeons and their teams, distributors and OEM partners around the world. With our expanding platform of industry-leading brands, including Quill® barbed sutures, Sharpoint® and Look™ surgical sutures, Katena® ophthalmic instruments and devices, Sharpoint ophthalmic knives, the TachoSil® fibrin sealant matrix, as well as Pearsalls and FSSB OEM solutions, Corza Medical delivers an exceptional customer experience and outstanding value to the entire surgical community. Find out more at http://corza.com